A Single Blood Draw Could Detect 50 Cancers — But Experts Have Questions
Finn's Take· TL;DR- FDA panel endorsed blood test detecting up to 50 cancers with cautious optimism, citing potential benefits despite unproven effectiveness.
- Test looks for cancer signals in single blood draw but requires follow-up testing; less accurate at catching early-stage disease.
- Approval could expand access via insurance coverage, but lack of mortality data means benefits remain theoretical rather than proven.
A Landmark Vote With an Asterisk
Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people — while warning that it's far from clear how well the technology works. The vote marks a pivotal moment in cancer medicine, one that could reshape how millions of Americans are screened for a disease that kills roughly 620,000 people in the U.S. every year.
The FDA's advisory panel voted 7-2, with one abstention, that the DNA-based test offers more potential benefits than risks, such as causing false assurances or raising false alarms. The positive vote came even as the panel raised many questions about the technology that need more study. "Perhaps my yes is a hopeful rather than an accurate one," said one panelist. That kind of cautious optimism captures the mood around this test perfectly — promising, but not yet proven.
What the Galleri Test Actually Does
A key advisory committee that reviews medical devices for the FDA recommended the agency approve the first multi-cancer blood test for people 50 and over. Grail, the company that makes the Galleri blood test, says it can detect up to 50 forms of cancer, most of which are not routinely screened for today. Think ovarian cancer, pancreatic cancer, thyroid cancer — diseases that are often discovered only after they've already spread.
The Galleri test doesn't diagnose cancer but instead, with a single blood draw, looks for a signal that someone may have one of a long list of tumors. Those who receive a positive result need additional care to determine if they're really sick. That's a critical distinction. A positive result is not a cancer diagnosis — it's a flag that warrants follow-up testing. The FDA estimates that about 58% of the nearly 630,000 U.S. cancer deaths expected in 2026 will involve cancer types without a U.S. Preventive Services Task Force screening recommendation. Pancreatic, ovarian, liver, and several other potentially serious cancers do not have routine population-wide screening programs comparable to mammography or colonoscopy.
The Very Real Concerns
FDA staffers and outside experts spent hours debating the potential downsides of the technology. Risks include that the test will miss a significant number of real cancers while also flagging a potential cancer in patients who are healthy. The test was also less accurate at detecting early-stage cancers — precisely when treatment is easier and more likely to benefit patients. That last point is especially troubling, since catching cancer early is the whole point.
Grail also didn't provide data showing that screening with its test led to fewer cancer deaths — a metric that would have required years of follow-up. That's the missing piece that scientists most want to see. Without evidence that the test actually saves lives, the endorsement rests largely on biological plausibility and early detection logic rather than hard mortality outcomes. Grail maintains the test is meant to complement existing screenings, not replace them.
What Comes Next — and What It Costs
People in the U.S. can already buy the Galleri test, typically by paying $700 or more in cash. But FDA approval would likely widen availability by opening the door to coverage from Medicare and private insurers. The test currently retails for $949 online — a price that puts it out of reach for many of the people who might benefit most. Full approval could change that dramatically.
Cancer is the second-leading cause of death in the United States. In recent years, nearly 620,000 deaths in the U.S. were due to cancer, with breast, lung and bronchus, prostate, and colorectal cancers accounting for nearly 50% of all new cases. The advisory panel's recommendation doesn't guarantee FDA approval, but it strongly signals the agency is moving in that direction. If approved, the Galleri test would represent the first FDA-sanctioned multi-cancer early detection tool — a milestone that could fundamentally change what a routine checkup looks like for adults over 50, provided the science continues to catch up with the promise.